Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature

In order to study alternatives at the tissue biopsy to study EGFR status in NSCLC patients, we evaluated three different liquid biopsy platforms (plasma, urine and exhaled breath condensate, EBC). We also reviewed the literature of the cfDNA biological sources other than plasma and compared our resu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Michela Verzè, Roberta Minari, Letizia Gnetti, Paola Bordi, Alessandro Leonetti, Agnese Cosenza, Leonarda Ferri, Maria Majori, Massimo De Filippo, Sebastiano Buti, Donatello Gasparro, Rita Nizzoli, Cinzia Azzoni, Lorena Bottarelli, Anna Squadrilli, Paola Mozzoni, Marcello Tiseo
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	non-small cell lung cancer EGFR-tyrosine kinase inhibitors liquid biopsy resistance mechanisms Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/baf6dfbf7bf446ec935f7672e54ef210
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:baf6dfbf7bf446ec935f7672e54ef210
record_format	dspace
spelling	oai:doaj.org-article:baf6dfbf7bf446ec935f7672e54ef2102021-11-11T15:30:20ZMonitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature10.3390/cancers132154032072-6694https://doaj.org/article/baf6dfbf7bf446ec935f7672e54ef2102021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5403https://doaj.org/toc/2072-6694In order to study alternatives at the tissue biopsy to study EGFR status in NSCLC patients, we evaluated three different liquid biopsy platforms (plasma, urine and exhaled breath condensate, EBC). We also reviewed the literature of the cfDNA biological sources other than plasma and compared our results with it about the sensitivity to EGFR mutation determination. Twenty-two EGFR T790M-mutated NSCLC patients in progression to first-line treatment were enrolled and candidate to osimertinib. Plasma, urine and EBC samples were collected at baseline and every two months until progression. Molecular analysis of cfDNA was performed by ddPCR and compared to tissue results. At progression NGS analysis was performed. The EGFR activating mutation detection reached a sensitivity of 58 and 11% and for the T790M mutation of 45 and 10%, in plasma and urine samples, respectively. Any DNA content was recovered from EBC samples. Considering the plasma monitoring study, the worst survival was associated with positive shedding status; both plasma and urine molecular progression anticipated the radiological worsening. Our results confirmed the role of plasma liquid biopsy in testing EGFR mutational status, but unfortunately, did not evidence any improvement from the combination with alternative sources, as urine and EBC.Michela VerzèRoberta MinariLetizia GnettiPaola BordiAlessandro LeonettiAgnese CosenzaLeonarda FerriMaria MajoriMassimo De FilippoSebastiano ButiDonatello GasparroRita NizzoliCinzia AzzoniLorena BottarelliAnna SquadrilliPaola MozzoniMarcello TiseoMDPI AGarticlenon-small cell lung cancerEGFR-tyrosine kinase inhibitorsliquid biopsyresistance mechanismsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5403, p 5403 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	non-small cell lung cancer EGFR-tyrosine kinase inhibitors liquid biopsy resistance mechanisms Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	non-small cell lung cancer EGFR-tyrosine kinase inhibitors liquid biopsy resistance mechanisms Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Michela Verzè Roberta Minari Letizia Gnetti Paola Bordi Alessandro Leonetti Agnese Cosenza Leonarda Ferri Maria Majori Massimo De Filippo Sebastiano Buti Donatello Gasparro Rita Nizzoli Cinzia Azzoni Lorena Bottarelli Anna Squadrilli Paola Mozzoni Marcello Tiseo Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
description	In order to study alternatives at the tissue biopsy to study EGFR status in NSCLC patients, we evaluated three different liquid biopsy platforms (plasma, urine and exhaled breath condensate, EBC). We also reviewed the literature of the cfDNA biological sources other than plasma and compared our results with it about the sensitivity to EGFR mutation determination. Twenty-two EGFR T790M-mutated NSCLC patients in progression to first-line treatment were enrolled and candidate to osimertinib. Plasma, urine and EBC samples were collected at baseline and every two months until progression. Molecular analysis of cfDNA was performed by ddPCR and compared to tissue results. At progression NGS analysis was performed. The EGFR activating mutation detection reached a sensitivity of 58 and 11% and for the T790M mutation of 45 and 10%, in plasma and urine samples, respectively. Any DNA content was recovered from EBC samples. Considering the plasma monitoring study, the worst survival was associated with positive shedding status; both plasma and urine molecular progression anticipated the radiological worsening. Our results confirmed the role of plasma liquid biopsy in testing EGFR mutational status, but unfortunately, did not evidence any improvement from the combination with alternative sources, as urine and EBC.
format	article
author	Michela Verzè Roberta Minari Letizia Gnetti Paola Bordi Alessandro Leonetti Agnese Cosenza Leonarda Ferri Maria Majori Massimo De Filippo Sebastiano Buti Donatello Gasparro Rita Nizzoli Cinzia Azzoni Lorena Bottarelli Anna Squadrilli Paola Mozzoni Marcello Tiseo
author_facet	Michela Verzè Roberta Minari Letizia Gnetti Paola Bordi Alessandro Leonetti Agnese Cosenza Leonarda Ferri Maria Majori Massimo De Filippo Sebastiano Buti Donatello Gasparro Rita Nizzoli Cinzia Azzoni Lorena Bottarelli Anna Squadrilli Paola Mozzoni Marcello Tiseo
author_sort	Michela Verzè
title	Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
title_short	Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
title_full	Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
title_fullStr	Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
title_full_unstemmed	Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
title_sort	monitoring cfdna in plasma and in other liquid biopsies of advanced egfr mutated nsclc patients: a pilot study and a review of the literature
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/baf6dfbf7bf446ec935f7672e54ef210
work_keys_str_mv	AT michelaverze monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT robertaminari monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT letiziagnetti monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT paolabordi monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT alessandroleonetti monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT agnesecosenza monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT leonardaferri monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT mariamajori monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT massimodefilippo monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT sebastianobuti monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT donatellogasparro monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT ritanizzoli monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT cinziaazzoni monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT lorenabottarelli monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT annasquadrilli monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT paolamozzoni monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature AT marcellotiseo monitoringcfdnainplasmaandinotherliquidbiopsiesofadvancedegfrmutatednsclcpatientsapilotstudyandareviewoftheliterature
_version_	1718435264562462720

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature

Ejemplares similares